menu ☰
menu ˟

Allergan, TARGET PharmaSolutions partner on ongoing NASH study

20 Apr 2017
Allergan will partner with TARGET PharmaSolutions on its TARGET-NASH study, a five-year longitudinal observational study of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children, according to a press release.“TARG...

Click here to view the full article which appeared in Gastroenterology

IPH Logo